ConductScience.org, home

Paper39504356

Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.

Ding J and 31 others. Sci Transl Med, 2024. Cited by 44 papers, by iCite.

Cite this record

ConductScience Library. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population. Papers, record 39504356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39504356

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.
PubMed
Journal
Sci Transl Med
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
44
iCite
Relative citation ratio, by iCite
5.38, provisional
iCite
Revised in PubMed
2026-03-07
PubMed

Authors32

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ding JJingjinghttps://orcid.org/0000-0003-1508-7084
2Liu HHuaizhenghttps://orcid.org/0009-0003-0131-9515
3Zhang XXiaoxunhttps://orcid.org/0000-0002-3892-7464
4Zhao NNanhttps://orcid.org/0000-0002-4597-6547
5Peng YYinghttps://orcid.org/0000-0003-4737-3712
6Shi JJunpinghttps://orcid.org/0000-0001-9434-897X
7Chen JJinjunhttps://orcid.org/0000-0003-4275-9149
8Chi XXiaolinghttps://orcid.org/0000-0003-3193-1943
9Li LLinghttps://orcid.org/0000-0002-9027-7307
10Zhang MMengni
11Liu WYWen-Yuehttps://orcid.org/0000-0003-4570-6835
12Zhang LLiangjun
13Ouyang JJiafeng
14Yuan QQian
15Liao MMin
16Tan YYa
17Li MMingqiao
18Xu ZZiqian
19Tang WWan
20Xie CChuanminghttps://orcid.org/0000-0003-4362-6612

Source PubMed

See all 32 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Non-alcoholic Fatty Liver DiseaseMajor topic
Female
Humans
Male
Middle Aged
China
Liver
Liver Cirrhosis
Liver Neoplasms
Metabolomics
Proteomics
Signal Transduction
East Asian People

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 DK134549NIDDK NIH HHSUnited StatesR01DK134549PubMed

Source NIH RePORTER

Download CSV of grants

Cited by42

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.

PMIDTitleJournalYearIn PapersSource
42953027Omics-derived signatures in metabolic dysfunction-associated steatotic liver disease: from molecular characterization to clinical translation.Front Med (Lausanne)2026https://conductscience.org/library/papers/42953027PubMed
42866058Omics-based Decoding of Metabolic Dysfunction-associated Fatty Liver Disease: From Pathogenesis to Clinical Translation.J Clin Transl Hepatol2026https://conductscience.org/library/papers/42866058PubMed
42823416Subtyping metabolic dysfunction-associated steatotic liver disease using electronic health record-linked genomic cohorts reveals diverse etiologies and progression.Nat Commun2026https://conductscience.org/library/papers/42823416PubMed
42793749An Attention-Residual Hybrid CNN for CT-Based Multiclass Classification of Alcohol-Related Liver Disease: Differential Diagnosis Against HBV-Related Cirrhosis.Diagnostics (Basel)2026https://conductscience.org/library/papers/42793749PubMed
42687025Molecular mechanisms and pathogenesis of MASH.Nature2026https://conductscience.org/library/papers/42687025PubMed
42687024Current therapeutic landscape and future treatment perspectives of MASH.Nature2026https://conductscience.org/library/papers/42687024PubMed
42627788Integrated liver transcriptomic data reveal differences in aging-associated regulation between metabolic dysfunction-associated steatotic liver disease and normal liver aging.PLoS One2026https://conductscience.org/library/papers/42627788PubMed
42396665Oral‑gut axis in systemic disease: A barrier‑metabolism‑immunity three‑dimensional regulatory model (Review).Int J Mol Med2026https://conductscience.org/library/papers/42396665PubMed
42317344Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma.Front Immunol2026https://conductscience.org/library/papers/42317344PubMed
42245952The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis.Front Med (Lausanne)2026https://conductscience.org/library/papers/42245952PubMed
42191458EASL position paper on preclinical models of steatotic liver disease.J Hepatol2026https://conductscience.org/library/papers/42191458PubMed
42189413Clinical clustering identifies MASLD subtypes with distinct longitudinal cardiovascular risks and lipidomic profiles.Hepatol Int2026https://conductscience.org/library/papers/42189413PubMed
42057080Metabolomic signatures of hepatic steatosis reveal heterogeneity in cardiometabolic risk and responses to lifestyle interventions in type 2 diabetes: a post hoc analysis.Cardiovasc Diabetol2026https://conductscience.org/library/papers/42057080PubMed
42036225[Precise clinical classification of metabolic associated fatty liver disease].Zhonghua Gan Zang Bing Za Zhi2026https://conductscience.org/library/papers/42036225PubMed
42021999Identification of novel therapeutic targets for liver fibrosis, cirrhosis, and hepatocellular carcinoma via dual-omics analysis and preliminary exploration of regulatory mechanisms.Clin Exp Hepatol2025https://conductscience.org/library/papers/42021999PubMed
41930175Comprehensive Bioinformatics Analysis and Experimental Verification RNF186 Is a Recurrence Signature Gene of Hepatocellular Carcinoma that Promotes Cell Proliferation.Oncol Res2026https://conductscience.org/library/papers/41930175PubMed
41928880Lipid metabolism-MAFLD crosstalk: mechanisms and therapy.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/41928880PubMed
41926040Targeting the Gut-Liver Mitochondria Axis in MASLD: Mechanisms and Therapeutic Perspectives.Curr Med Sci2026https://conductscience.org/library/papers/41926040PubMed
41851447Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/41851447PubMed
41826328Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD.Nat Commun2026https://conductscience.org/library/papers/41826328PubMed

See all 42 cited byDownload CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39504356

GET https://conductscience.org/api/papers/v1/39504356/authors?page=2